Weekly Digest – May 2025 Weekly Digest – May 2025 19 May 2025: Blenrep (Belantamab mafodotin) combinations approved in Japan for treatment of relapsed/refractory multiple Myeloma GSK’s Blenrep in combination with bortezomib plus dexamethasone (BVd) and in combination with pomalidomide […]
Weekly Digest – May 2025 Weekly Digest – May 2025 19 May 2025: Zai Lab receives U.S. FDA fast track designation for ZL-1310, a DLL3-targeted ADC, for treatment of extensive-stage small cell Lung cancer The FDA has granted fast track […]
Weekly Digest – May 2025 Weekly Digest – May 2025 19 May 2025: CPO301 granted the third fast track designation by US FDA for the treatment of adult patients with NSCLC CPO301 (SYS6010 in China) has received its third fast […]
Weekly Digest – May 2025 Weekly Digest – May 2025 22 May 2025: Avenzo Therapeutics announces FDA clearance of Investigational New Drug application for AVZO-1418, a potential best-in-class, novel EGFR/HER3 bispecific antibody-drug conjugate Avenzo Therapeutics received FDA clearance for its […]
Weekly Digest – May 2025 Weekly Digest – May 2025 22 May 2025: Fourth NDA for Kelun-Biotech’s TROP2 ADC Sacituzumab tirumotecan (sac-TMT) accepted by the Center for Drug Evaluation The NMPA’s Center for Drug Evaluation (CDE) accepted a new application […]
Weekly Digest – May 2025 Weekly Digest – May 2025 20 May 2025: Antengene enters into a global clinical collaboration with MSD to evaluate ATG-022 (CLDN18.2 ADC) in combination with KEYTRUDA (Pembrolizumab) Antengene has entered a global clinical collaboration with […]
